abatacept
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Primary Biliary Cirrhosis
Conditions
Primary Biliary Cirrhosis
Trial Timeline
Sep 1, 2014 → Oct 1, 2018
NCT ID
NCT02078882About abatacept
abatacept is a approved stage product being developed by Bristol Myers Squibb for Primary Biliary Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02078882. Target conditions include Primary Biliary Cirrhosis.
What happened to similar drugs?
20 of 20 similar drugs in Primary Biliary Cirrhosis were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05170672 | Pre-clinical | Completed |
| NCT05981976 | Phase 1 | Completed |
| NCT04925375 | Phase 2 | Recruiting |
| NCT04472494 | Phase 2 | Terminated |
| NCT04477642 | Phase 1/2 | Withdrawn |
| NCT03924401 | Phase 2 | Active |
| NCT03882008 | Approved | Completed |
| NCT03669861 | Phase 2 | Completed |
| NCT03714022 | Phase 1 | Completed |
| NCT03084419 | Phase 2 | UNKNOWN |
| NCT03215927 | Phase 2 | Completed |
| NCT02915159 | Phase 3 | Completed |
| NCT02805010 | Phase 1 | UNKNOWN |
| NCT02037737 | Pre-clinical | Completed |
| NCT02592798 | Phase 2 | Completed |
| NCT02598466 | Pre-clinical | Completed |
| NCT02281058 | Phase 1 | UNKNOWN |
| NCT02078882 | Approved | Completed |
| NCT01954979 | Phase 1 | Completed |
| NCT02169544 | Pre-clinical | Completed |
Competing Products
20 competing products in Primary Biliary Cirrhosis